Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03235024 · ClinicalTrials.gov registry record · Phase 2
Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis
A Phase 2 study, sponsored by AOBiome.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT03235024 is a Phase 2 study that has completed, run by AOBiome. The registered enrollment target is 122 participants.
The verdict
NCT03235024, a Phase 2 study, has completed, sponsored by AOBiome.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 28 days vs vehicle application on treatment of mild to moderate AD
Interventions
- BIOLOGICAL Vehicle
- BIOLOGICAL B244
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2018-01-15 |
| Est. Completion | 2019-03-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03235024
The ClinicalTrials.gov registry entry for NCT03235024 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AOBiome, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT03235024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03235024 about?
NCT03235024 is a clinical study titled "Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis". This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 28 days vs vehicle application on treatment of mild to moderate AD
What is the current status of trial NCT03235024?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2018-01-15. Estimated completion is 2019-03-20.
What interventions are being tested in trial NCT03235024?
The interventions under investigation include: Vehicle (BIOLOGICAL), B244 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03235024?
This trial is sponsored by AOBiome, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.